Qingfang Miao
Impact in
-
- HER2/EGFR in Cancer Research
- Peptidase Inhibition and Analysis
- CAR-T cell therapy research
-
- Monoclonal and Polyclonal Antibodies Research
- Radiopharmaceutical Chemistry and Applications
Papers in
- Oncology 18
- HER2/EGFR in Cancer Research 8
- Peptidase Inhibition and Analysis 4
-
- Chemical Synthesis and Analysis 4
- Co-authors
- Yong‐Su Zhen (22 shared papers)Shenghua Zhang (6 shared papers)Xiujun Liu (8 shared papers)Yi Li (3 shared papers)Jianhua Gong (5 shared papers)Rong Wang (2 shared papers)Bo-Yang Shang (3 shared papers)Genshen Zhong (4 shared papers)
In The Last Decade
Qingfang Miao
30 papers receiving 334 citations
Peers
Comparison fields: 5 of 62
- Oncology 145
- Radiology, Nuclear Medicine and Imaging 102
- Microbiology 24
- Molecular Biology 177
- Structural Biology 3
Countries citing papers authored by Qingfang Miao
This map shows the geographic impact of Qingfang Miao's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Qingfang Miao with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Qingfang Miao more than expected).
Fields of papers citing papers by Qingfang Miao
This network shows the impact of papers produced by Qingfang Miao. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Qingfang Miao. The network helps show where Qingfang Miao may publish in the future.
Co-authors
The 25 scholars most cited alongside Qingfang Miao, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 30 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | 2022 | 37 | |
| 2 | 2018 | 31 | |
| 3 | 2010 | 29 | |
| 4 | 2018 | 28 | |
| 5 | 2016 | 26 | |
| 6 | 2018 | 22 | |
| 7 | 2020 | 16 | |
| 8 | 2012 | 15 | |
| 9 | 2019 | 12 | |
| 10 | 2009 | 12 | |
| 11 | 2017 | 12 | |
| 12 | 2021 | 11 | |
| 13 | 2021 | 11 | |
| 14 | 2020 | 9 | |
| 15 | 2011 | 9 | |
| 16 | 2012 | 7 | |
| 17 | 2007 | 7 | |
| 18 | 2022 | 6 | |
| 19 | 2022 | 6 | |
| 20 | 2011 | 5 |
About Qingfang Miao
Qingfang Miao is a scholar working on Oncology, Molecular Biology, Radiology, Nuclear Medicine and Imaging, Organic Chemistry and Pathology and Forensic Medicine, having authored 30 papers that have together received 338 indexed citations. Recurring topics across this work include Monoclonal and Polyclonal Antibodies Research (11 papers), HER2/EGFR in Cancer Research (8 papers), Antimicrobial Peptides and Activities (4 papers), Chemical Synthesis and Analysis (4 papers), Toxin Mechanisms and Immunotoxins (4 papers), Lymphoma Diagnosis and Treatment (4 papers), Peptidase Inhibition and Analysis (4 papers) and Cyclization and Aryne Chemistry (3 papers). The work is most often cited by research in Oncology (145 citations), Radiology, Nuclear Medicine and Imaging (102 citations), Microbiology (24 citations), Molecular Biology (177 citations) and Structural Biology (3 citations). Qingfang Miao has collaborated with scholars based in China, France and Canada. Frequent co-authors include Yong‐Su Zhen, Shenghua Zhang, Xiujun Liu, Yi Li, Jianhua Gong, Rong Wang, Bo-Yang Shang, Genshen Zhong, Ruijuan Gao and Jigang Yang. Their work appears in journals such as Cancer Letters, Cancer Biology & Therapy, European Journal of Nuclear Medicine and Molecular Imaging, Molecular Oncology and European Journal of Pharmaceutical Sciences.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.